Botulinum toxin type A-targeted SPP1 contributes to neuropathic pain by the activation of microglia pyroptosis
Notably, BTX-A therapy and SPP1 shRNA enhance microglial proliferation and apoptosis and inhibit microglial death. It improves pain perception and inhibits microglial activation in rats with selective nerve pain.
Authors
- Houming Kan (ORCID: https://orcid.org/0000-0001-5792-2901)
- Xiaodie Gui (ORCID: https://orcid.org/0009-0004-9809-8305)
- Jinzhao Huang (ORCID: https://orcid.org/0000-0001-5930-6651)
- Liping Chen (ORCID: https://orcid.org/0000-0001-8062-0717)
- Fu‐Hai Ji (ORCID: https://orcid.org/0000-0002-3269-3417)
- Wen-Di Tian
Institutions
- Macau University of Science and Technology (MO)
- Xuzhou Medical College (CN)
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- World Journal of Psychiatry
- Published
- 2024-08-12
- DOI
- https://doi.org/10.5498/wjp.v14.i8.1254
- Citations
- 6
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.21